JNJ250110C137000
- 7.55
- 0.000.00%
Johnson & Johnson Newsroom
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $160
San Francisco Police Cancel Time Off as Healthcare Execs Descend -- Barrons.com
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events
J&J Stock Falls After Company Pauses Use of Heart Device
Johnson & Johnson Falls After Pausing Varipulse Cases
8 Health Care Stocks Whale Activity In Today's Session
Express News | J&J - as U.S. External Evaluation Leveraged Unique Platform Configuration, There Is No Impact to Commercial Activity & Varipulse Cases Outside of U.s
Express News | J&J: On Jan 5, Johnson & Johnson Medtech Temporarily Paused U.S. External Evaluation and All U.S. Varipulse Cases
Express News | Johnson & Johnson Statement on Varipulse™ U.S. External Evaluation
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Merck, Johnson & Johnson Share Losses Lead Dow's 180-Point Fall
Johnson & Johnson on Track for Lowest Close Since November 2020 -- Data Talk
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's
Express News | Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $177
Johnson & Johnson (JNJ) Gets a Hold From Bernstein
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
Johnson & Johnson (NYSE:JNJ) Jumps to Year's High on Lung Cancer Drug Success
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181